Table 2.
Comparison of Patient Tumor and TLBR-1 Cell Line to Primary Systemic, Primary Cutaneous, and Seroma-Associated ALCLs
| Primary Systemic ALCL | Primary Cutaneous ALCL | Seroma- Associated ALCL | Primary Tumor Specimen | TLBR-1 Cell Line & SCID Heterotransplant | |
|---|---|---|---|---|---|
| CD30 | + | + | + | + | + |
| TCRγ monoclonality | + | + | + | + | + |
| ALK | + (60–80%) | − (Rarely +) | − (Rarely +) | − | − |
| t(2;5) | + (60–80%) | − | − | − | − |
| EMA | + | − | + | + | Weak |
| Clinical course | Aggressive | Indolent | Indolent | Indolent | NA |